TCG, an international life sciences consulting firm, is celebrating 20 years of providing strategic advisory services and interim management to its worldwide clients.
Founded in 1998 by three life science executives in the Research Triangle Park, North Carolina, TCG has served large and small US, European and Asian clients in the medical device, pharmaceutical, biotechnology and other life science industries. While TCG began by helping US life science companies establish and grow their businesses, TCG soon realized that its services were especially valuable to mid-sized ex-US companies interested in entering the US market.
TCG Partner Dennis Burns recalled his early days with TCG, helping a German medical device company build a direct sales force in the US. “We could see that there was a bridge needed for international companies wanting to enter the US market. They had a great product, but not the market knowledge, regulatory and reimbursement strategy or commercial network to penetrate the US market. That’s where TCG came in.” Over the past 20 years, TCG has helped life science companies from all of the major EU countries expand their presence in the US market.
TCG currently has seven Partners in the US and in Europe. Jan Turek, who joined TCG in 2012, is typical of TCG’s partners — he’s led biotechnology start-ups as well as business units of large multinational life science companies and has been based on both sides of the Atlantic during his career. His practice concentrates on providing interim management and strategic advisory services to biopharmaceutical clients, from emerging companies looking to find partnerships with big Pharma, to larger clients looking to refine strategy, acquire new assets or launch a major product.
Ken West, a TCG founder, reflected on the firm’s successes over the past twenty years: “We’ve worked side-by-side with our clients as their businesses were undergoing fundamental change, whether entering new international markets or acquiring other companies. It has been a privilege to work with these visionaries, and help them commercialize new products and technologies that improve people’s health and people’s lives.”